A Hub-And-Spoke BiotechPortfolio CompanyDone Differently

CinRock PharmaCinPressa PharmaCinDome PharmaCinCor PharmaGraviton BiosciencevTv TherapeuticsCinRock PharmaCinPressa PharmaCinDome PharmaCinCor PharmaGraviton BiosciencevTv TherapeuticsCinRock PharmaCinPressa PharmaCinDome PharmaCinCor PharmaGraviton BiosciencevTv Therapeutics

CapitalExpertiseExecution

Too many promising medicines fail to reach patients due to development hurdles rather than scientific limitations. At CinRx Pharma, we bridge that gap, propelling high-potential therapeutics forward with strategic capital, deep expertise, and infrastructure built on insights from thousands of clinical programs.

The CinRx operating model

Our structure empowers innovation through efficiency. We establish asset-focused portfolio companies, known as ‘CinCos,’ designed to operate within a streamlined management framework. This allows each asset to advance rapidly without the traditional burdens of early-stage biotech building.

Discover our model

  1. Centralized execution engine

    Cross-functional experts power every program from one shared team.

  2. Frictionless capital deployment

    Resources flow dynamically to the assets that need them at inflection points.

  3. Strategic CRO Partner

    Medpace partnership for global trial operations and navigating regulatory pathways.

Our portfolio

We pursue medicines that address significant unmet patient needs and have the potential to meaningfully improve outcomes. Our rigorous identification and diligence process informs a highly selective acquisition strategy, resulting in a differentiated portfolio across multiple disease areas.

  • CinRock Pharma

    Selective ROCK2 inhibition for cardiovascular diseases

    Visit CinRock Pharma
  • CinPressa Pharma

    Developing a long-term, backbone siRNA therapy for hypertension

    Visit CinPressa Pharma
  • CinDome Pharma

    Restoring quality of life for patients with gastroparesis.

    Visit CinDome Pharma
  • CinCor Pharma

    Acquired by AstraZeneca.

    Visit the product site

Newsroom

Stay up to date with the latest updates across the CinRx portfolio of companies.

  1. CinRx Pharma

    Graviton BioScience and CinRx Pharma Form CinRock Pharma to Advance ROCK2-Targeted Therapies for Cardiovascular Disease

    Graviton BioScience and CinRx Pharma form CinRock Pharma to advance ROCK2-targeted therapies for cardiovascular disease.

    Read story
  2. CinDome Pharma

    CinDome Pharma Announces Completion of Enrollment in the envisionGI Phase 2 Study of Deudomperidone (CIN-102) for the Treatment of Idiopathic Gastroparesis

    CinDome announced the completion of patient enrollment in its envisionGI Phase 2 clinical study evaluating deudomperidone (CIN-102) for the treatment of idiopathic gastroparesis.

    Read story
  3. CinDome Pharma

    CinDome Pharma Announces Enrollment Completion in the envision3D Phase 2 Clinical Trial of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis

    CinDome announced enrollment completion in its envision3D Phase 2 trial evaluating deudomperidone (CIN-102) for the treatment of diabetic gastroparesis.

    Read story
More news
Connect

Let's advance medicine, together

Whether you're a clinical investigator, a potential partner, or considering joining our team - we'd like to hear from you.

Start a conversationPartnering inquiries